Filing Flows › 4D Molecular Therapeutics (FDMT) › Q1 2025
4D Molecular Therapeutics (FDMT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
4D Molecular Therapeutics (FDMT) reported revenue of $14K for the first quarter 2025 (Q1 2025), -50% from a year earlier and up 14-fold from the quarter before.
4D Molecular Therapeutics, Q1 2025: revenue $14K (-50% year over year), net loss $48.0M, operating cash flow −$47.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14K | 14× | -50% |
| Operating profit | −$53.6M | — | — |
| Net earnings | −$48.0M | — | — |
| Operating cash flow | −$47.8M | — | — |
What changed
Revenue was $14K in Q1 2025, down 50% year over year and up 1300% from the previous quarter.
Operating costs exceeded revenue by $53.6M, an operating margin of -383007.1%. Total costs grew 41% against a revenue fall of 50%. The fastest-growing cost line was Research & development (+46%). The quarter ended with a net loss of $48.0M, narrower than the previous quarter's $49.7M loss.
Operating cash flow was −$47.8M. Non-cash charges added back $1.1M of depreciation and amortization and $7.0M of share-based compensation. Working capital and other items used $7.8M. Capital expenditures of $631K exceeded it, leaving free cash flow of −$48.4M.
Questions
What was 4D Molecular Therapeutics' revenue in the first quarter 2025?
4D Molecular Therapeutics (FDMT) reported revenue of $14K for the first quarter 2025 (Q1 2025), -50% from a year earlier and up 14-fold from the quarter before.